| Bioactivity | Maridebart cafraglutide is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity[1][2]. |
| CAS | 2887445-76-1 |
| Molar Mass | 153,514 (average) |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bloomgarden Z T. The 2023 WCIRDC: Obesity[J]. Journal of Diabetes, 2024, 16(4). [2]. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. |
Maridebart cafraglutide
CAS: 2887445-76-1 F: W: 153,514 (average)
Maridebart cafraglutide is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.